

1. [AstraZeneca's lung cancer drug meets main goal in late-stage trial](#) – Reuters

AstraZeneca Plc said its experimental lung cancer drug Tagrisso met its main goal in a late-stage study. The tablet, which has won early approval from both U.S. and European regulators, is one of several cancer medicines AstraZeneca hopes will rebuild its sales following patent losses on older drugs. AstraZeneca said Tagrisso showed superior progression-free survival compared to standard platinum-based chemotherapy.

2. [China approves use of GSK vaccine Cervarix for cervical cancer](#) – Reuters

Drugmaker GlaxoSmithKline Plc said on Monday the China Food and Drug Administration (CFDA) has approved its human papillomavirus (HPV) vaccine, Cervarix, for use in the country to help women fight cervical cancer. GSK's China unit said in a statement Cervarix will be the first HPV vaccine licensed for use in the country and is expected to be launched there in early 2017.

3. [Meet India's next generation of women leaders in pharma](#) – The Economic Times

The Indian pharmaceutical and healthcare industry has long been dominated by men, a trait it shares with many of its counterparts abroad. But now a big change is sweeping across this immensely technical and challenging business landscape. A new crop of women business leaders has emerged at the top, coming up with game-changing ideas and services in some of India's top pharma and healthcare companies. Their business acumen apart, these women have added tremendous value in shaping their organisations.

4. [Abbott looking for buyer to sell low-end brands](#) – The Economic Times

Abbott, the second largest drug maker in India, is hunting for a buyer to sell its tail-end brands, a move that highlights the consolidation woes of large acquisitions in India, according to two people familiar with the development. Abbott, which acquired the generic business of Piramal Healthcare in 2010 for \$3.72 billion, has been looking to cut down the portfolio of products that are of low margin, besides being present in a crowded therapy space.

5. [Regulatory price controls reduce investments, not cost](#) – Mint

Inflation, monetarists claim, is a monetary phenomenon as long as supply-side shocks are not there. That is like claiming to have the spouse's permission to say that one is the boss of the house. Supply-side changes happen slowly and are greatly influenced by micro rigidities in that

1. [AstraZeneca's lung cancer drug meets main goal in late-stage trial](#) – Reuters
2. [China approves use of GSK vaccine Cervarix for cervical cancer](#) – Reuters
3. [Meet India's next generation of women leaders in pharma](#) – The Economic Times
4. [Abbott looking for buyer to sell low-end brands](#) – The Economic Times
5. [Regulatory price controls reduce investments, not cost](#) – Mint
6. [Sun Pharma gets epilepsy drug licence for US market](#) – The Times of India
7. [25% Indians at risk of premature death from non-communicable diseases: WHO](#) – The Times of India
8. [Ajanta Pharma launches acid reflux drug in US](#) – India Today
9. [Glenmark Pharma plans to raise around \\$200 mn by issuing non-convertible unsecured bonds](#) – Indiainfoline.com
10. [Peregrine licenses exosome-based cancer detection & monitoring technology from UT Southwestern Medical Center](#) – Pharmabiz.com

particular industry or segment. One such micro rigidity is regulatory control of prices. In the face of high inflation, the government tries to moderate it by controlling prices. Such control of prices looks like the right thing to do, but in fact it is exactly the wrong thing to do.

6. [Sun Pharma gets epilepsy drug licence for US market](#) – The Times of India

Sun Pharmaceutical group on Monday announced the licensing of ELEPSIA XR drug by Sun Pharma Advanced Research Company Ltd (SPARC) to a subsidiary of Sun Pharmaceutical Industries Ltd for the US market. In a statement, Sun Pharma said SPARC will licence ELEPSIA XR (Levetiracetam Extended Release tablets) to a wholly-owned subsidiary for the US market. SPARC will receive an up-front payment of \$10 million from Sun Pharma apart from certain additional milestone payments and defined royalties linked to any future sales of ELEPSIA XR.

7. [25% Indians at risk of premature death from non-communicable diseases: WHO](#) – The Times of India

Premature deaths from cancer, heart disease, diabetes and lung diseases have jumped to 70 per cent of all global deaths in 2015 from 42 per cent three years ago (in 2012), posing a major threat to sustainable development of nations, says WHO's latest assessment on non-communicable diseases (NCDs). In India, one in four risk dying from NCDs before reaching 70 years of age, representing the largest cause of death.

8. [Ajanta Pharma launches acid reflux drug in US](#) – India Today

Ajanta Pharma has launched generic omeprazole and sodium bicarbonate capsules, used in the treatment of acid reflux and ulcers, in the US market after receiving final approval from the country's health regulator.

The company has launched the product in the US through its wholly-owned subsidiary, Ajanta Pharma USA Inc, Ajanta Pharma said in a filing to BSE. The approval from the United States Food and Drug Administration (USFDA) is for the capsules in the strengths of 20mg/1100 mg and 40 mg/1100 mg, it added.

9. [Glenmark Pharma plans to raise around \\$200 mn by issuing non-convertible unsecured bonds](#) – [Indiainfoline.com](#)

Glenmark Pharmaceuticals Ltd has informed BSE that subsequent to the rating received by the leading credit agencies in the world i.e. S&P and Fitch, Glenmark Pharmaceuticals limited has decided to tap into the International Bond market and is planning to raise around USD 200 mn by issuing USD denominated non-convertible unsecured bonds. The net proceeds will be used for repaying the existing debt. These bonds are planned to be listed on the Singapore Stock Exchange in order to establish the Company's track record in the globally recognized bond market.

10. [Peregrine licenses exosome-based cancer detection & monitoring technology from UT Southwestern Medical Center](#) – [Pharmabiz.com](#)

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, announced that the company has entered into an exclusive licensing agreement with University of Texas (UT) Southwestern Medical Center for a novel exosome technology that has potential application as a simple blood test to detect or monitor cancer. The company intends to develop a novel cancer test utilizing internal expertise and then pursue revenue-generating partnering opportunities at an early stage of development. Tumour exosomes represent small pieces of tumour cells that are released into the blood as tumours grow. tumour derived exosomes have phosphatidylserine (PS) on their surface as a detectable marker. It is believed that even small tumours begin to release PS-positive exosomes and thus the ability to detect these exosomes in the blood may be an indicator of the presence of a tumour.